John Wilding; Rachel L. Batterham; Salvatore Calanna; Melanie J. Davies; Luc F. Van Gaal; Ildiko Lingvay; Barbara McGowan; Julio Rosenstock; Marie Thi Dao Tran; Thomas A. Wadden; Sean Wharton; Koutaro Yokote; Niels Zeuthen; Robert F. Kushner · 2021 · New England Journal of Medicine
Paper
BACKGROUND: Obesity is a global health challenge with few pharmacologic options. Whether adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 mg as an adjunct to lifestyle intervention has not been confirmed. METHODS: In this double-blind trial, we enrolled 1961 adults with a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or greater (≥27 in persons with ≥1 weight-related coexisting condition), who did not have diabetes, and randomly assigned them, in a 2:1 ratio, to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention. The coprimary end points were the percentage change in body weight and weight reduction of at least 5%. The primary estimand (a precise description of the treatment effect reflecting the objective of the clinical trial) assessed effects regardless of treatment discontinuation or rescue interventions. RESULTS: The mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group as compared with -2.4% with placebo, for an estimated treatment difference of -12.4 percentage points (95% confidence interval [CI], -13.4 to -11.5; P<0.001). More participants in the semaglutide group than in the placebo group achieved weight reductions of 5% or more (1047 participants [86.4%] vs. 182 [31.5%]), 10% or more (838 [69.1%] vs. 69 [12.0%]), and 15% or more (612 [50.5%] vs. 28 [4.9%]) at week 68 (P<0.001 for all three comparisons of odds). The change in body weight from baseline to week 68 was -15.3 kg in the semaglutide group as compared with -2.6 kg in the placebo group (estimated treatment difference, -12.7 kg; 95% CI, -13.7 to -11.7). Participants who received semaglutide had a greater improvement with respect to cardiometabolic risk factors and a greater increase in participant-reported physical functioning from baseline than those who received placebo. Nausea and diarrhea were the most common adverse events with semaglutide; they were typically transient and mild-to-moderate in severity and subsided with time. More participants in the semaglutide group than in the placebo group discontinued treatment owing to gastrointestinal events (59 [4.5%] vs. 5 [0.8%]). CONCLUSIONS: In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight. (Funded by Novo Nordisk; STEP 1 ClinicalTrials.gov number, NCT03548935).
Analysis
A 68-week trial demonstrated that once-weekly semaglutide (2.4 mg) combined with lifestyle intervention resulted in a mean body weight reduction of 14.9% in adults with overweight or obesity, compared to 2.4% with placebo.
Discovery
Sean Wharton; Louis J. Aronne; Adam Stefański; Nasreen Alfaris; Andreea Ciudin; Koutaro Yokote; Bruno Halpern; Alpana P. Shukla; Chunmei Zhou; Lisa Macpherson; Sheryl Allen; Nadia N. Ahmad; Suzanne Klise
Nadia J Abbass; Raya Nahlawi; Jacqueline K. Shaia; Kevin Allan; David C. Kaelber; Katherine E. Talcott; Rishi P. Singh
Roger S. McIntyre; Rodrigo B. Mansur; Joshua D. Rosenblat; Angela T.H. Kwan
A. Michael Lincoff; Kirstine Brown‐Frandsen; Helen M. Colhoun; John Deanfield; Scott S. Emerson; Sille Esbjerg; Søren Hardt‐Lindberg; G. Kees Hovingh; Steven E. Kahn; Robert F. Kushner; Ildiko Lingvay; Tuğçe Kalaycı Oral; Marie Mide Michelsen; Jorge Plutzky; Christoffer W. Tornøe; Donna H. Ryan
Jingyue Wang; Quanwei Wang; Xinyu Yang; Wei Yang; Dong-Rui Li; Jingyu Jin; Hui-Cong Zhang; Xianfeng Zhang
Xin Zhao; Minghe Wang; Zhitong Wen; Zhihong Lu; Lijuan Cui; Chao Fu; Huan Xue; Yunfeng Liu; Yi Zhang
Source record